REVIEW Etravirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), designed to be active against HIV with mutations that confer resistance to the two most commonly prescribed first-generation NNRTIs, mutation K103N for efavirenz and Y181C for nevirapine.
REFERENCES
[1]
Minuto, Joshua J.; Haubrich, Richard. Etravirine: a second-generation NNRTI for treatment-experienced adults with resistant HIV-1 infection. Future HIV Therapy. (2008) 2(6): 525-537.
[2]
Seminari, E.; Castagna, A.; Lazzarin, A. Etravirine for the treatment of HIV infection. Expert Review of Anti-Infective Therapy. (2008) 6(4): 427-433.
[3]
Scholler-Gyure, Monika; Kakuda, Thomas N.; Raoof, Araz; De Smedt, Goedele; Hoetelmans, Richard M. W. Clinical pharmacokinetics and pharmacodynamics of etravirine. Clinical Pharmacokinetics. (2009) 48(9): 561-574.
[4]
De Corte, Bart; De Jonge, Marc Rene; Heeres, Jan; Ho, Chih Yung; Janssen, Paul Adriaan Jan; Kavash, Robert W.; Koymans, Lucien Maria Henricus; Kukla, Michael Joseph; Ludovici, Donald William; Van Aken, Koen Jeanne AlfonsPreparation of arylaminopyrimidines as inhibitors of HIV replication. PCT Int. Appl. (2000), WO 2000027825 A1 20000518.
All products are stocked and shipped from the SF Bay, California, USA via FedEx, UPS or DHL.
All batches backed with full quality assurance.
??
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.
Add to Favorites 
Delete from Favorites 
